Soligenix Enhances Advisory Board to Advance HyBryte™ for Cutaneous T-Cell Lymphoma Treatment

Soligenix Strengthens Advisory Board to Propel HyBryte™ Development for Rare Cancer Treatment

Soligenix, Inc., a biopharmaceutical company focused on treatments for rare diseases, announces a strategic update to its U.S. Medical Advisory Board (MAB) aimed at enhancing the clinical development of HyBryte™ (synthetic hypericin), specifically for cutaneous T-cell lymphoma (CTCL). This rare form of non-Hodgkin's lymphoma presents unique challenges in treatment, and the updated MAB, consisting of leading dermatologic and oncologic experts, plays a crucial role in navigating these complexities. The board’s expertise is particularly important as Soligenix progresses through the ongoing FLASH2 Phase 3 pivotal clinical trial, which is critical for regulatory approval and future commercialization.

The recent changes to the MAB include the addition of key opinion leaders who have previously acted as principal investigators in the HyBryte™ clinical program. These experts bring not only a wealth of knowledge about the drug but also valuable insights into the clinical landscape surrounding CTCL. Their involvement is expected to enhance the strategic direction of the clinical development plan, particularly in addressing the specific needs of CTCL patients. The board will focus on clinical strategies, potential home-use applications, and economic considerations regarding health care reimbursement, all of which are vital for ensuring that HyBryte™ meets the expectations of both patients and health authorities.

Dr. Christopher J. Schaber, President and CEO of Soligenix, expresses optimism about the new members' contributions, noting their extensive experience with HyBryte™ and the overall clinical landscape. The collaboration aims to optimize treatment solutions for CTCL patients and facilitates the successful worldwide commercialization of HyBryte™. This move highlights Soligenix's commitment to addressing unmet medical needs in rare diseases, as well as its dedication to integrating expert guidance into its clinical strategy to improve outcomes and accessibility for patients.

In addition to strengthening its advisory board, Soligenix's focus on rare disease treatment reinforces its position in the biopharmaceutical landscape. The company seeks to leverage the specialized knowledge of its MAB to navigate regulatory pathways and enhance the patient experience. By prioritizing strategic collaborations, Soligenix aims to ensure that its innovative therapies bring meaningful improvements to the lives of those suffering from rare conditions.

Overall, Soligenix's proactive approach in updating its Medical Advisory Board illustrates its commitment to advancing the development of HyBryte™ and addressing the critical needs of patients with CTCL. As the FLASH2 trial progresses, the insights and strategies derived from the MAB are poised to play a significant role in shaping the future of treatment for this challenging cancer.